ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2011) 25 P103

Testosterone undecanoate has a beneficial effect on lipid profile in men with hypogonadism in routine clinical practice

Vakkat Muraleedharan1,2, Christen Rolfe1, Nishant Ranjan3 & Hugh Jones1,2


1Barnsley Hospital NHS Foundation Trust, Barnsley, UK; 2University of Sheffield, Sheffield, UK; 3Doncaster Royal Infirmary, Doncaster, UK.


Background: There is a close association between low testosterone and metabolic syndrome. Testosterone replacement therapy (TRT) has beneficial effects on cardiovascular (CV) risk factors in men with hypogonadism.

Aim: This is a retrospective audit of CV parameters in hypogonadal men treated with testosterone undecanoate (Nebido) in standard clinical practice.

Methods: Patients with hypogonadism on testosterone undecanoate injections from 2005 to 2009 were identified from hospital data base. Weight, blood pressure, non-fasting lipid profile and HbA1c (diabetic men n=42) were collected at 3, 6, and 12 months.

Results: Of the 120 patients 99 (82%) had previous TRT with other preparations. Mean age was 48±16 years. After excluding patients with changes in lipid lowering medications over the treatment period, the total cholesterol (TC) and calculated LDL cholesterol (cLDL) demonstrated significant improvement.

TC at 3 months was 3.8±1.4 (compared with 4.6 mmol/l±1.4 at baseline P=0.006, n=47), at 6 months 4.2±1.3 (P=0.03, n=36) and at 1 year 4.1±1.1 (P=0.005, n=41).

cLDL at 3 months was 1.9 mmol/l±1 (vs 2.3±1.1 at baseline; P=0.006, n=43) at 6 months 2.1±1 (P=0.13, n=38) and at 12 months 2.1±1 (P=0.046, n=33).

HDL-cholesterol (HDL) did not show any significant change at 6 months 1.05±0.3 (vs 1.08±0.3 at baseline P=0.33, n=44) or at 12 months 1.04±0.28 (P=0.08, n=35).

At 12 months no significant changes in weight (98 vs 99 kg; P=0.09, n=67) or blood pressure (SBP 135 vs 137 P=0.3 DBP 78 vs 80 P=0.2, n=69) were noted. HbA1c fell by 0.4% (P=0.07) at 6 months in diabetic patients.

Discussion: Testosterone undecanoate therapy in routine clinical practice had beneficial effects on total cholesterol and cLDL, but no significant effect on HDL. No effects were found on weight and blood pressure.

Article tools

My recent searches

No recent searches.